Search
                    Grand Rapids, MI Paid Clinical Trials
A listing of 417  clinical trials  in Grand Rapids, MI  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            145 - 156 of 417
        
                There are currently 417 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Spectrum Health - Butterworth Campus, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you. 
            
                                        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
                                
            
            
        Recruiting
                            
            
                The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/07/2025
            
            Locations: Research Site, Grand Rapids, Michigan         
        
        
            Conditions: Non-squamous Non-small Cell Lung Cancer
        
            
        
    
                
                                    Pompe Disease Registry Protocol
                                
            
            
        Recruiting
                            
            
                The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of t...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                08/06/2025
            
            Locations: Spectrum for Health- Site Number : 840019, Grand Rapids, Michigan  +1 locations         
        
        
            Conditions: Glycogen Storage Disease Type II, Pompe Disease
        
            
        
    
                
                                    A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
                                
            
            
        Recruiting
                            
            
                This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/06/2025
            
            Locations: START Midwest - Oncology, Grand Rapids, Michigan         
        
        
            Conditions: Advanced Breast Cancer
        
            
        
    
                
                                    Total Shoulder Arthroplasty Multi-Center Registry
                                
            
            
        Recruiting
                            
            
                The objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                08/06/2025
            
            Locations: Not set, Grand Rapids, Michigan         
        
        
            Conditions: Shoulder Arthroplasty
        
            
        
    
                
                                    Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
                                
            
            
        Recruiting
                            
            
                The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.             
        
        
    Gender:
                MALE
            Ages:
                Between 18 years and 130 years
            Trial Updated:
                08/06/2025
            
            Locations: Research Site, Grand Rapids, Michigan         
        
        
            Conditions: Metastatic Castration-Sensitive Prostate Cancer
        
            
        
    
                
                                    64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
                                
            
            
        Recruiting
                            
            
                This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).             
        
        
    Gender:
                ALL
            Ages:
                15 years and above
            Trial Updated:
                08/06/2025
            
            Locations: BAMF Health, Inc., Grand Rapids, Michigan         
        
        
            Conditions: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
        
            
        
    
                
                                    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
                                
            
            
        Recruiting
                            
            
                This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
It will also study what side effects happen when participants get the drug. A side effect is anything a drug does...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/06/2025
            
            Locations: Cancer & Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan  +1 locations         
        
        
            Conditions: Urothelial Carcinoma
        
            
        
    
                
                                    Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
                                
            
            
        Recruiting
                            
            
                The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).
All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.             
        
        
    Gender:
                ALL
            Ages:
                3 years and above
            Trial Updated:
                08/06/2025
            
            Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan         
        
        
            Conditions: Spinal Muscular Atrophy, Spine Deformity, Scoliosis
        
            
        
    
                
                                    A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/06/2025
            
            Locations: START Midwest, Grand Rapids, Michigan         
        
        
            Conditions: Advanced Solid Tumors
        
            
        
    
                
                                    A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
                                
            
            
        Recruiting
                            
            
                This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806.
Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/06/2025
            
            Locations: Clinical Trial Site, Grand Rapids, Michigan         
        
        
            Conditions: KRAS G12D Mutation, Advanced Solid Cancer
        
            
        
    
                
                                    Intra-Corporeal Anastomosis Result in Quicker Return of Bowel Function/Earlier Discharge
                                
            
            
        Recruiting
                            
            
                Adult patients who are regularly scheduled to undergo a right hemicolectomy via a minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/05/2025
            
            Locations: Spectrum Health Medical Group, Grand Rapids, Michigan         
        
        
            Conditions: Colorectal Disorders
        
            
        
    
                
                                    Citadel Embolization Device Study
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to gather safety and effectiveness data on Stryker Neurovascular's Next Generation Target Detachable Coil (hereafter referred to as the Citadel Embolization Device), when used with Target Detachable Coils, in the treatment of wide-neck intracranial aneurysms.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                08/05/2025
            
            Locations: Spectrum Health, Grand Rapids, Michigan         
        
        
            Conditions: Unruptured Wide-neck Aneurysms
        
            
        
    145 - 156 of 417
            